RxDoctor Payments Data

Jay Wright, DO

Interventional Cardiology · Dallas, TXNPI 1932158292

Payments from drug & device makers

$4,141in general payments, 2019–2025

Across 216 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$676
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$619
  • Edwards Lifesciences$425
  • Abbott$284
  • E.r. Squibb & Sons, L.L.C.$278
  • Johnson & Johnson$267
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,141100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,141 in reported general payments places this provider in the 20th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$8,838
Medicare patients
93
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$252,176
EliquisApixaban92$89,530
EntrestoSacubitril/Valsartan20$17,413
FarxigaDapagliflozin Propanediol16$15,777
Nitroglycerin41$1,551
ClopidogrelClopidogrel Bisulfate147$1,545
Metoprolol Succinate138$1,198
Flecainide Acetate21$959
Losartan Potassium90$918
Torsemide30$879
Atorvastatin Calcium75$699
Colchicine20$654
Nifedipine ErNifedipine29$620
Carvedilol84$526
Amiodarone Hcl52$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$232$341,706103 claims
NovartisEntresto$223$17,41320 claims
AstraZenecaFarxiga$112$15,77716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →